We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Improved Molecular Breast Imaging Screening System Receives CE Marking

By MedImaging International staff writers
Posted on 26 Oct 2015
Print article
A breast imaging medical device manufacturer has announced that their Molecular Breast Imaging (MBI) system, intended for women with dense breast tissue, has received the European CE Marking.

The MBI screening system is already in use in leading hospitals in the US following approval by the US Food and Drug Administration (FDA) in 2011. The system is intended for the screening and early detection of breast cancer in women with dense breast tissue for whom conventional mammography and screening with other modalities is insufficient.

CE Marking approval of the LumaGEM MBA screening system was announced by the manufacturer, Gamma Medica (Salem, NH, USA), a women’s health company, and enables the company to sell and distribute the system in the European Economic Area (EEA).

Nearly one in 10 women in Europe develops breast cancer before the age of 80, making it the common cancer affecting women. Conventional mammography has less sensitivity when imaging dense breast tissue – both dense tissue and cancerous areas appear white on the mammogram. At the same time women with dense breast have an increased risk of developing breast cancer. A recent has shown that the addition of MBI screening test to an annual mammogram resulted in a nearly 400% percent increase in detection rates of invasive breast cancer. The use of MBI screening also resulted in 50% less biopsies, and cost savings of 15% per cancer detected, compared to only screening with conventional mammography.

MBI is a functional imaging modality and can show activity and detect tumors in dense tissue, whereas other modalities such as ultrasound, Magnetic Resonance Imaging (MRI), and tomosynthesis, are anatomical imaging systems. MBI is also useful for high-risk patients, and those who cannot undergo an MRI exam.

Philip M. Croxford, President and CEO of Gamma Medica, said, “Securing the CE Mark for the LumaGEM MBI system represents a major step forward in our commercialization plans to market this technology to benefit women with dense breast tissue in Europe. By offering the best MBI solution to physicians, we are helping them manage their patients’ risk efficiently by providing a highly accurate and cost-efficient secondary breast cancer screening for women with complex mammograms and dense breast tissue.”

Related Links:

Gamma Medica


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Computed Tomography (CT) Scanner
Aquilion Serve SP
MRI System
uMR 588
New
Portable Radiology System
DRAGON ELITE & CLASSIC

Print article

Channels

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.